Kintor Pharma’s GT20029 Phase II trial meets primary endpoint

Kintor Pharma has announced positive results from its GT20029 Phase II trial in China for treating male androgenetic alopecia (AGA), meeting the primary endpoint.

The trial evaluated the efficacy and safety of GT20029 tincture, Kintor Pharma's internally developed androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound.

Conducted across 12 clinical research centers in China, the Phase II trial was a multicenter, randomized, double-blind, placebo-controlled study, demonstrating statistical and clinical significance, along with good safety and tolerability.

The primary endpoint was the change in non-vellus target area hair counts (TAHC) after 12 weeks of treatment compared to placebo.

Results showed that GT20029 tincture significantly improved hair counts compared to placebo in both once-daily (QD) and twice-weekly (BIW) dosing cohorts.

The 0.5% QD group exhibited a 16.80 hairs/cm² increase, while the 1% BIW group showed an 11.94 hairs/cm² increase, with no reported adverse sexual events, and a similar incidence of adverse events to placebo.